Abstract Valve‐in‐valve (ViV) procedures for failing bioprostheses carry a certain risk for
device malfunction. We herein report a case of a failing Evolut R in a deteriorated Mitroflow …

Transcatheter heart valve aortic valve-in-valve (ViV) implantation is likely to become
increasingly important for the treatment of patients with degenerated and failing …

Recently, small case series have described the successful off-label use of transcatheter
valve implantation in patients with degenerated bioprosthetic valves in the mitral position …

We present a case of left ventricular outflow tract (LVOT) obstruction after double valve re-
replacement with bioprostheses. A 72-year-old man, who had undergone double valve …

Objectives: The aim of this study was to determine whether the association of small label
size of the surgical valve with increased mortality after transcatheter valve-in-valve (ViV) …

Transcatheter valve-in-valve (VIV) procedures are less invasive than re-do open heart
surgery, and have proven relatively safe and effective. In large multicentre registries …

Aortic bioprosthesis failure in high-risk patients who are not candidates for operation has
been ameliorated with transcatheter aortic valve replacement. As of last year, more than …

OBJECTIVES: The Mitroflow aortic pericardial bioprosthesis was widely employed in the
past. However, some authors have recently reported early structural valve deterioration …

3. Discussion VIV is a good alternative treatment for degenerated surgical bioprostheses but
exhibits some challenges when compared to TAVI in native valves. First, especially in those …

Background Transcatheter valve-in-valve implantation (ViV) has evolved as a viable strategy
in suitable cases of patients with a failed surgical bioprosthesis heat valves (SHV) …